World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
75
Citations
15148
World Ranking
5442
National Ranking
2581

Research.com Recognitions

  • 2014 - Fellow, National Academy of Inventors
  • 2004 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Ching-Shih Chen is affiliated with The Ohio State University in the United States. Their academic profile shows recognition through prestigious awards, reflecting involvement in notable scientific communities.

Chen has been honored as a Fellow of the American Association for the Advancement of Science (AAAS) since 2004. This fellowship signifies membership in an organization dedicated to furthering science and its applications. In 2014, Chen was also named a Fellow of the National Academy of Inventors, indicating contributions to innovation and invention.

Information about Chen's publications and collaborative networks is not detailed in the available data. Likewise, specific research topics, primary fields of study, and subfields associated with their work are not enumerated.

The absence of recent paper titles, frequent co-authors, publication venues, and book publishers limits a comprehensive overview of Chen's academic output. However, the recognitions received highlight a sustained engagement with research and innovation within their field.

Best Publications

  • FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemia

    Paolo Neviani;Ramasamy Santhanam;Joshua J. Oaks;Anna M. Eiring

  • Suberoylanilide Hydroxamic Acid Reactivates HIV From Latently Infected Cells

    Xavier Contreras;Marc Schweneker;Ching-Shih Chen;Joseph M. McCune

  • Indole-3-carbinol as a chemopreventive and anti-cancer agent.

    Jing-Ru Weng;Chen-Hsun Tsai;Samuel K. Kulp;Ching-Shih Chen

  • From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors

    Jiuxiang Zhu;Jui Wen Huang;Ping Hui Tseng;Ya Ting Yang

  • 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells.

    Samuel K. Kulp;Ya Ting Yang;Chin Chun Hung;Kuen Feng Chen

  • Cyclooxygenase-2, Player or Spectator in Cyclooxygenase-2 Inhibitor-Induced Apoptosis in Prostate Cancer Cells

    Xueqin Song;Ho Pi Lin;Amy J. Johnson;Ping Hui Tseng

  • Targeting histone deacetylase in cancer therapy

    Hsiang Yu Lin;Chang Shi Chen;Shuan Pei Lin;Jing Ru Weng

  • Neutrophil gelatinase-associated lipocalin as a survival factor

    Zhimin Tong;Xuli Wu;Dmitriy Ovcharenko;Jiuxiang Zhu

  • PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

    Paolo Neviani;Jason G. Harb;Joshua J. Oaks;Ramasamy Santhanam

  • Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARγ

    Chung Wai Shiau;Chih Cheng Yang;Samuel K. Kulp;Kuen Feng Chen

  • Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes.

    Chang Shi Chen;Shu Chuan Weng;Ping Hui Tseng;Ho Pi Lin

  • Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents that Produce DNA Double-Strand Breaks by Targeting Ku70 Acetylation

    Chang Shi Chen;Yu Chieh Wang;Hsiao Ching Yang;Po Hsien Huang

  • Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents.

    Jiuxiang Zhu;Xueqin Song;Ho-Pi Lin;Donn C. Young

  • Small-Molecule Inhibitors of Phosphatidylinositol 3-Kinase/Akt Signaling Inhibit Wnt/β-Catenin Pathway Cross-Talk and Suppress Medulloblastoma Growth

    Ninib Baryawno;Baldur Sveinbjörnsson;Staffan Eksborg;Ching-Shih Chen

  • OSU-03012, a Novel Celecoxib Derivative, Induces Reactive Oxygen Species–Related Autophagy in Hepatocellular Carcinoma

    Ming Gao;Pei Yen Yeh;Yen-Shen Lu;Chih-Hung Hsu

  • Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia

    Leslie A. Andritsos;Amy J. Johnson;Gerard Lozanski;William Blum

  • AMPK Reverses the Mesenchymal Phenotype of Cancer Cells by Targeting the Akt–MDM2–Foxo3a Signaling Axis

    Chih-Chien Chou;Kuen-Haur Lee;I-Lu Lai;Dasheng Wang

  • FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.

    Qing Liu;Xiaobin Zhao;Frank Frissora;Yihui Ma

  • Peroxisome Proliferator-Activated Receptor γ-Independent Ablation of Cyclin D1 by Thiazolidinediones and Their Derivatives in Breast Cancer Cells

    Jui Wen Huang;Chung Wai Shiau;Ya Ting Yang;Samuel K. Kulp

  • Increased PTEN expression due to transcriptional activation of PPARγ by Lovastatin and Rosiglitazone

    Rosemary E. Teresi;Chung-Wai Shaiu;Ching-Shih Chen;V. Krishna Chatterjee

Frequent Co-Authors

John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Guido Marcucci
Guido Marcucci City Of Hope National Medical Center
Michael A. Caligiuri
Michael A. Caligiuri City Of Hope National Medical Center
James T. Dalton
James T. Dalton St. Jude Children's Research Hospital
Michael R. Grever
Michael R. Grever The Ohio State University
Charles L. Shapiro
Charles L. Shapiro Icahn School of Medicine at Mount Sinai
Robert J. Lee
Robert J. Lee University of Pennsylvania
Che-Ming Teng
Che-Ming Teng National Taiwan University
L. James Lee
L. James Lee The Ohio State University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Ching-Shih Chen

Trending Scientists

Recently Published Articles